Patient satisfaction with finasteride in the treatment of symptomatic benign prostatic hyperplasia

被引:7
|
作者
Kaplan, SA
Olsson, CA
机构
[1] Columbia-Presbyterian Medical Center, New York, NY
[2] Columbia-Presbyterian Medical Center, New York, NY 10032, 622 W. 168th St.
关键词
D O I
10.1016/S0149-2918(96)80180-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The type and magnitude of urinary symptoms, the behavioral adjustments necessitated by such symptoms, and the degree of patient satisfaction with treatment and current health were evaluated in 102 men with symptomatic benign prostatic hyperplasia (BPH) who had been receiving finasteride for 9 to 12 months. We also evaluated these variables in a group of 109 men who had under one transurethral resection of the prostate (TURF) for symptomatic BPH 9 to 12 months before the study. A validated, patient-directed telephone questionnaire was used to solicit information. Men with BPH who continued to receive finasteride therapy for at least 9 months experienced considerable symptomatic relief during the first year of therapy, and reported a high degree of satisfaction with their urinary condition. Urinary symptoms either resolved or occurred only rarely in the majority of men treated with finasteride. Most of the BPH patients taking finasteride (78%) indicated that urinary symptoms did not restrict their participation in normal activities. Fifty-four percent of finasteride patients rated their current health as excellent or very good, and 87% indicated that their current condition represented an improvement over their pretreatment state. Responses in the men treated with TURF reinforced previous observations about the effectiveness of this treatment in men with symptomatic BPH. Thus in the appropriate patient group, finasteride represents an effective management option for symptomatic BPH.
引用
收藏
页码:73 / 83
页数:11
相关论文
共 50 条
  • [21] Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia
    Marks, LS
    Partin, AW
    Gormley, GJ
    Dorey, FJ
    Shery, ED
    Garris, JB
    Subong, ENP
    Stoner, E
    deKernion, JB
    JOURNAL OF UROLOGY, 1997, 157 (06): : 2171 - 2178
  • [22] FINASTERIDE (MK-906) IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
    MOCELLINI, AI
    GARDINER, R
    MARSHALL, V
    JOHNSON, W
    BARTSCH, G
    SCHMIDBAUER, CP
    MOSSING, H
    VANCANGH, PJ
    DENIS, LJ
    ARAP, S
    FREIRE, GC
    DELATORRE, D
    BOTTO, H
    RICHARD, F
    DEVONEE, M
    TEILLAC, P
    VALLANCIEN, G
    BRAF, Z
    DISILVERIO, F
    MIANO, L
    PAGANO, F
    GABILONDO, F
    DEBRUYNE, F
    JANKNEGT, RA
    SCHROEDER, FH
    NACEY, J
    FURTADO, LA
    CARRETERO, P
    JIMENEZ, FC
    HAURI, D
    OTTO, U
    ALBRECHT, J
    ALTWEIN, JE
    EGGHART, G
    ENGELMANN, U
    JACOBI, GH
    KREYES, G
    PANIJEL, M
    RIEDASCH, G
    RUGENDORFF, EW
    FABRICIUS, P
    OBOYLE, PJ
    GINGELL, C
    BUCK, AC
    CHARIG, C
    GRINO, P
    FERGUSON, D
    ROUND, E
    SHIH, J
    STONER, E
    PROSTATE, 1993, 22 (04): : 291 - 299
  • [23] Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia
    Magoha, GAO
    EAST AFRICAN MEDICAL JOURNAL, 1998, 75 (05) : 260 - 263
  • [24] Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia
    Bhardwa, Jeetesh
    Goldstraw, Miles
    Tzortzis, Sevasti
    Kirby, Roger
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (09) : 1337 - 1344
  • [25] FINASTERIDE - A REVIEW OF ITS POTENTIAL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
    PETERS, DH
    SORKIN, EM
    DRUGS, 1993, 46 (01) : 177 - 208
  • [26] Medical treatment of benign prostatic hyperplasia: physician and patient preferences and satisfaction
    Emberton, M.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (10) : 1425 - 1435
  • [27] Combined analysis of two multicenter studies of finasteride 5 mg in the treatment of symptomatic benign prostatic hyperplasia
    CA Byrnes
    CL Liss
    JL Tenover
    MC Lippert
    JY Gillenwater
    Prostate Cancer and Prostatic Diseases, 1997, 1 : 26 - 31
  • [28] Combined analysis of two multicenter studies of finasteride 5 mg in the treatment of symptomatic benign prostatic hyperplasia
    Byrnes, CA
    Liss, CL
    Tenover, JL
    Lippert, MC
    Gillenwater, JY
    PROSTATE CANCER AND PROSTATIC DISEASES, 1997, 1 (01) : 26 - 31
  • [29] Terazosin, finasteride, or both in benign prostatic hyperplasia
    Kuchel, GA
    DuBeau, CE
    Resnick, NM
    NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (04): : 293 - 294
  • [30] THE EFFECT OF FINASTERIDE IN MEN WITH BENIGN PROSTATIC HYPERPLASIA
    GORMLEY, GJ
    STONER, E
    BRUSKEWITZ, RC
    IMPERATOMCGINLEY, J
    WALSH, PC
    MCCONNELL, JD
    ANDRIOLE, GL
    GELLER, J
    BRACKEN, BR
    TENOVER, JS
    VAUGHAN, ED
    PAPPAS, F
    TAYLOR, A
    BINKOWITZ, B
    NG, J
    NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (17): : 1185 - 1191